Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus

NCT00407069 | Completed DMC

• 1 other identifier: DAIT ADVN AMP 01
• Study Type: observational
• Target: 286
• Locations: 1 country
• Sites: 1

Brief Summary

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. Recent studies have demonstrated that the skin of people with AD my have decreased antimicrobial peptide (AMP) expression. The purpose of this study is to compare smallpox virus replication and the number of AMPs and other antiviral molecules in people with AD, as compared to those seen in people with psoriasis or asthma, or healthy individuals.

Conditions

Atopic Dermatitis

Outcome Measures

Primary Outcomes (1)

• Expression of vaccinia virus mRNA in non-lesional skin following inoculation with untreated vaccinia virus will be evaluated using real-time RT-PCR (Reverse transcription polymerase chain reaction).

  5 years

Secondary Outcomes (5)

• Expression of cytokines, AMPs, other antiviral molecules, or epidermal differentiation proteins in non-lesional skin prior to and after inoculation with vaccinia virus will be evaluated using real-time RT-PCR.

  5 years

• Keratinocytes will be stimulated with vaccinia virus in the presence and absence of Th1 or Th2 cytokines. Non-lesional AD skin will be stimulated with vaccinia virus in the presence of antibodies that neutralize Th2 cytokines.

  5 years

• Vaccinia virus replication will be evaluated using a standard viral plaque assay in BS-C-1 cells and by analyzing vaccinia virus mRNA expression using real-time RT-PCR in keratinocytes and BS-C-1 cells.

  5 years

• Expression of over 20,000 genes will be evaluated by GeneChip microarrays in non-lesional skin, and PBMCs stimulated with vaccinia virus. Real-time RT-PCR of skin and PBMC will be used to confirm gene alterations found in GeneChip microarrays.

  5 years

• Ability of structural analogues of CSAs (Cyclosporine) to kill purified vaccinia virus as well as keratinocytes infected with vaccinia virus in vitro.

  5 years

Study Arms (6)

Active Atopic Dermatitis (AD)

Pediatric and adult subjects who fulfill the criteria for AD, a chronic inflammatory skin disease.

Inactive Atopic Dermatitis (AD)

Adult subjects with a prior history of active AD that has been quiescent for at least 1 year.

Psoriatics

Adult subjects who fulfill the criteria for plaque psoriasis, a chronic inflammatory skin disease.

Asthmatics (without a history of AD)

Adult subjects who fulfill the criteria for asthma (reactive airway disease) and have a negative history of skin disease.

Eczema Herpeticum (EH

Pediatric and adult AD subjects with a history of EH.

Healthy Volunteers

Healthy individuals with no history of skin or respiratory disease.

Eligibility Criteria

• Age: 2 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

People of good general health

You may qualify if:

• years of age or older
• History of active or inactive AD OR eczema herpeticum, as defined by the ADVN standardized diagnostic criteria
• Parent or guardian willing to provide informed consent, if applicable
• Male or female of any race and ethnicity
• years or older
• History of psoriasis OR history of asthma not requiring systemic medications
• Parent or guardian willing to provide informed consent, if applicable
• Male or female of any race and ethnicity

You may not qualify if:

• Oral corticosteroids or any systemic immunosuppressive or immunomodulatory medication within 28 days prior to study entry
• Immunotherapy within 3 months prior to study entry
• History of bleeding disorder
• Aspirin, oral antihistamines, oral antibiotics, oral cyclosporine, or topical medications within 7 days of screening visit including, but not restricted to, Protopic, Elidel, topical corticosteroids, and topical antibiotics
• Anxiolytic agents and antidepressants within 2 days of screening visit
• Diabetic requiring medication
• Autoimmune or immunodeficiency
• Active fungal, bacterial, or viral infections within 7 days prior to study entry
• Active systemic cancer. Participants with uncomplicated nonmelanoma skin cancer are not excluded.
• Theophylline or leukotriene antagonists within 24 hours of screening visit
• Received any vaccination within 30 days prior to study entry
• Known lidocaine allergy
• Previously vaccinated for smallpox
• Pregnant or breastfeeding

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead

Study Sites (1)

National Jewish Health

Denver, Colorado, 80207, United States

Location

Related Publications (7)

• Howell MD, Jones JF, Kisich KO, Streib JE, Gallo RL, Leung DY. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol. 2004 Feb 1;172(3):1763-7. doi: 10.4049/jimmunol.172.3.1763.

  PMID: 14734759 BACKGROUND

• Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung DY. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol. 2003 Sep 15;171(6):3262-9. doi: 10.4049/jimmunol.171.6.3262.

  PMID: 12960356 BACKGROUND

• Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C, Pavicic T, Boguniewicz M, Leung DY. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol. 2006 Apr;117(4):836-41. doi: 10.1016/j.jaci.2005.12.1345. Epub 2006 Feb 14.

  PMID: 16630942 BACKGROUND

• Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004 Mar;113(5):651-7. doi: 10.1172/JCI21060.

  PMID: 14991059 BACKGROUND

• Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Streib JE, Leung DY. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity. 2006 Mar;24(3):341-8. doi: 10.1016/j.immuni.2006.02.006.

  PMID: 16546102 RESULT

• Howell MD, Gao P, Kim BE, Lesley LJ, Streib JE, Taylor PA, Zaccaro DJ, Boguniewicz M, Beck LA, Hanifin JM, Schneider LC, Hata TR, Gallo RL, Kaplan MH, Barnes KC, Leung DY. The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections. J Allergy Clin Immunol. 2011 Nov;128(5):1006-14. doi: 10.1016/j.jaci.2011.06.003. Epub 2011 Jul 18.

  PMID: 21762972 RESULT

• Grigoryev DN, Howell MD, Watkins TN, Chen YC, Cheadle C, Boguniewicz M, Barnes KC, Leung DY. Vaccinia virus-specific molecular signature in atopic dermatitis skin. J Allergy Clin Immunol. 2010 Jan;125(1):153-159.e28. doi: 10.1016/j.jaci.2009.10.024.

  PMID: 20109744 RESULT

Related Links

• National Institute of Allergy and Infectious Diseases (NIAID)
• Division of Allergy, Immunology, and Transplantation (DAIT)

Biospecimen

Retention: SAMPLES WITH DNA

Blood and skin samples will be retained

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Donald Leung, MD, PhD

  National Jewish Health

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 30, 2006
• First Posted: December 4, 2006
• Study Start: June 1, 2005
• Primary Completion: February 1, 2010
• Study Completion: February 1, 2010
• Last Updated: October 18, 2016

Record last verified: 2016-10

Data Sharing

• IPD Sharing: Will share

Locations

US (1)